Heart and Vascular
Sapere Bio is developing a series of products to optimize critical treatment decisions for patients with heart and vascular disease, beginning with those that require cardiac surgery and other interventions that put them at-risk of treatment-related adverse events, prolonged recovery, and long-term compromise.
AKI-Sapere is a pre-operative blood test that uses senescence to stratify patients by risk of acute kidney injury (AKI) before cardiac surgery.
Unpredictable kidney injury
30% of cardiac surgery patients experience AKI with devastating consequences.
Surgeons cannot predict which patients are vulnerable based on common clinical variables
(sCr, eGFR, diabetes, age).
AKI interventions are limited and applied post-op, long after injury.
Preventable with AKI-Sapere
80% of AKI cases can be predicted before surgery.
Pre- and intra-operative interventions can prevent or reduce the severity of AKI.
Patients, physicians, and hospitals benefit from better surgical outcomes.
Studied at leading cardiovascular centers
Based on rigorous, prospective clinical studies
Although our technology addresses the whole-body milieu and has applications throughout medicine, our products (predictive senescence-based algorithms) are derived from rigorous clinical studies and optimized for specific clinical decision points.
Discovered at Duke and
The predictive value of senescence in cardiac surgery was discovered in a real-world, observational study at Johns Hopkins and Duke.
Multi-Center Validation Study Ongoing
A large clinical validation study, GUARD-AKI, is ongoing at Johns Hopkins, WakeMed Heart and Vascular, and Hoag Memorial Hospital with completion expected in early 2022.